Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reply to “Quality control requirements for the correct annotation of lipidomics data”

    Research output: Contribution to journalLetterResearchpeer-review

  4. Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Ultraviolet radiation drives mutations in a subset of mucosal melanomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1

    Research output: Contribution to journalReviewResearchpeer-review

  5. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  • STOP-HCV Consortium
View graph of relations

Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver disease, worldwide. With the development of direct-acting antivirals, treatment of chronically infected patients has become highly effective, although a subset of patients responds less well to therapy. Sofosbuvir is a common component of current de novo or salvage combination therapies, that targets the HCV NS5B polymerase. We use pre-treatment whole-genome sequences of HCV from 507 patients infected with HCV subtype 3a and treated with sofosbuvir containing regimens to detect viral polymorphisms associated with response to treatment. We find three common polymorphisms in non-targeted HCV NS2 and NS3 proteins are associated with reduced treatment response. These polymorphisms are enriched in post-treatment HCV sequences of patients unresponsive to treatment. They are also associated with lower reductions in viral load in the first week of therapy. Using in vitro short-term dose-response assays, these polymorphisms do not cause any reduction in sofosbuvir potency, suggesting an indirect mechanism of action in decreasing sofosbuvir efficacy. The identification of polymorphisms in NS2 and NS3 proteins associated with poor treatment outcomes emphasises the value of systematic genome-wide analyses of viruses in uncovering clinically relevant polymorphisms that impact treatment.

Original languageEnglish
Article number6105
JournalNature Communications
Volume12
Issue number1
Pages (from-to)1-11
Number of pages11
ISSN2041-1723
DOIs
Publication statusPublished - 20 Oct 2021

Bibliographical note

© 2021. The Author(s).

    Research areas

  • Antiviral Agents/therapeutic use, Genome, Viral/genetics, Genotype, Hepacivirus/drug effects, Hepatitis C, Chronic/drug therapy, Humans, Polymorphism, Genetic, Sofosbuvir/therapeutic use, Treatment Failure, Viral Load/drug effects, Viral Nonstructural Proteins/genetics

ID: 68558504